William van der Touw

William van der Touw has extensive work experience in the field of translational research and immunology. William has held various roles at Celularity Inc. from 2017 to 2023, including Senior Vice President of Translational and Discovery Research. In this role, they led a team responsible for translational research, early R&D, and strategy for allogeneic cell therapy product development. William worked closely with research, clinical, and regulatory teams, managing external collaborations and overseeing clinical trials in hematology and solid tumor spaces. Prior to Celularity, William worked at Celgene as a Senior Scientist in Translational Immunology from 2016 to 2017, where they designed and analyzed translational assays for cell therapy products. William also has experience as a Postdoctoral Fellow at the Icahn School of Medicine at Mount Sinai, where they focused on developing antibodies and studying monocyte and macrophage biology in tumor microenvironments. Additionally, they conducted research on regulatory T cells and NK cells in models of GVHD, colitis, and solid organ transplantation. William began their career as a Research Associate at Organon, where they worked on functional assays for drug candidates in cancer immunotherapy and autoimmunity. Currently, they are a Senior Vice President at Actinium Pharmaceuticals, Inc. in the Research & Development department.

William van der Touw earned a PhD in Immunology from the Icahn School of Medicine at Mount Sinai between 2007 and 2013. Prior to that, they obtained an AB degree in Biochemical Sciences from Harvard University from 2001 to 2005. Before attending Harvard, they attended Polytechnic School from 1997 to 2001, though it is unclear whether they obtained a degree or field of study from that institution.